Revolution Medicines, Inc. Increase (Decrease) in Contract with Customer, Liability
Revolution Medicines, Inc. (RVMD) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-02-25
- Revolution Medicines, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-12-31 was $0.00.
- Revolution Medicines, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-09-30 was $0.00.
- Revolution Medicines, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-06-30 was $0.00.
- Revolution Medicines, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-03-31 was $0.00.
- Revolution Medicines, Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was $0.00.
- Revolution Medicines, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was $0.00.
- Revolution Medicines, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was -$4.46M.
- Revolution Medicines, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$14.47M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | -$1.43M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | -$1.43M derived: sum of 3 quarters · filed 2026-02-25 | -$4.46M 10-K · filed 2026-02-25 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$1.43M derived: sum of 2 quarters · filed 2024-11-06 | -$4.46M 10-Q · filed 2024-11-06 | -$15.10M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$4.46M 10-Q · filed 2024-08-07 | -$15.10M derived: sum of 3 quarters · filed 2025-02-26 | -$13.52M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$3.02M 10-Q · filed 2024-05-08 | -$13.67M derived: sum of 2 quarters · filed 2025-02-26 | -$12.09M derived: sum of 3 quarters · filed 2025-02-26 | -$15.66M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$10.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$9.06M derived: sum of 2 quarters · filed 2025-02-26 | -$12.64M derived: sum of 3 quarters · filed 2025-02-26 | -$14.47M 10-K · filed 2025-02-26 |
| 2022-09-30 | $1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$1.99M derived: sum of 2 quarters · filed 2023-11-06 | -$3.83M 10-Q · filed 2023-11-06 | -$7.24M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$3.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$5.41M 10-Q · filed 2023-08-08 | -$8.82M derived: sum of 3 quarters · filed 2024-02-26 | -$2.44M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$1.84M 10-Q · filed 2023-05-08 | -$5.25M derived: sum of 2 quarters · filed 2024-02-26 | $1.14M derived: sum of 3 quarters · filed 2024-02-26 | -$1.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | -$3.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $2.97M derived: sum of 2 quarters · filed 2024-02-26 | $832.00K derived: sum of 3 quarters · filed 2024-02-26 | -$1.66M 10-K · filed 2024-02-26 |
| 2021-09-30 | $6.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $4.24M derived: sum of 2 quarters · filed 2022-11-07 | $1.75M 10-Q · filed 2022-11-07 | -$539.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$2.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$4.63M 10-Q · filed 2022-08-09 | -$6.92M derived: sum of 3 quarters · filed 2023-02-27 | -$10.23M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$2.49M 10-Q · filed 2022-05-09 | -$4.78M derived: sum of 2 quarters · filed 2023-02-27 | -$8.09M derived: sum of 3 quarters · filed 2023-02-27 | -$10.72M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$5.60M derived: sum of 2 quarters · filed 2023-02-27 | -$8.23M derived: sum of 3 quarters · filed 2023-02-27 | -$11.26M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$3.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$5.94M derived: sum of 2 quarters · filed 2021-11-10 | -$8.97M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$2.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$5.66M 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | -$3.03M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | -$13.39M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |